Publications in collaboration with researchers from Hospital Regional Universitario de Málaga (18)

2009

  1. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

    European Journal of Cancer, Vol. 45, Núm. 10, pp. 1877-1889

  2. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

  3. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

    Molecular Cancer, Vol. 8, pp. 69

2008

  1. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582

  2. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

  3. Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia

    Cancer Science, Vol. 99, Núm. 9, pp. 1865-1868

  4. Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia

    Leukemia Research, Vol. 32, Núm. 3, pp. 487-490

  5. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation

    Leukemia Research, Vol. 32, Núm. 5, pp. 709-716

2007

  1. Epigenetic regulation of PRAME gene in chronic myeloid leukemia

    Leukemia Research, Vol. 31, Núm. 11, pp. 1521-1528

  2. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia

    Blood, Vol. 109, Núm. 8, pp. 3462-3469

  3. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia

    Haematologica, Vol. 92, Núm. 2

  4. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia

    European Journal of Cancer, Vol. 43, Núm. 18, pp. 2736-2746

2006

  1. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia

    Oncogene, Vol. 25, Núm. 13, pp. 1862-1870

  2. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia

    International Journal of Cancer, Vol. 118, Núm. 8, pp. 1945-1953

  3. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia

    Clinical Cancer Research, Vol. 12, Núm. 16, pp. 4845-4850

  4. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter

    British Journal of Haematology, Vol. 134, Núm. 2, pp. 137-144

  5. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome [5]

    Leukemia

2005

  1. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia

    Oncogene, Vol. 24, Núm. 48, pp. 7213-7223